Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solution is also provided.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A, 1B and 1C illustrate the absorbance (Figs A and B) and correlation coefficient (C) characteristics of riboflavin derivative form alpha prepared in accordance with embodiments described herein.
Claims
1. A method of increasing the concentration of an alloxazine in an aqueous medium to above the alloxazine's saturation point, the method comprising:
adding an amount of said alloxazine to said aqueous medium, wherein the amount of alloxazine exceeds the saturation point of said alloxazine at 1 atmosphere and 22° C.;heating said aqueous medium to a temperature equal to or greater than 80° C.; andcooling said aqueous medium to produce an aqueous medium having a concentration of alloxazine above the alloxazine saturation point.
2. The method of claim 1, wherein the alloxazine is added before said heating step.
3. The method of claim 1, wherein the alloxazine is added after said heating step.
4. The method of claim 1, wherein the aqueous medium has a pH of between about 4 and about 5.
5. The method of claim 1, wherein the aqueous medium has a temperature of between about 80° C. and about 90° C.
6. The method of claim 1, wherein the aqueous medium further comprises a monovalent salt.
7. The method of claim 1, wherein the alloxazine is riboflavin.
8. The method of claim 1, further comprising sterilizing the aqueous medium under pressure at a temperature of at least 120° C.
9. A method for inactivating pathogens in a biological fluid comprising:
adding a composition comprising at least 120 μM soluble alloxazine to the biological fluid to inactivate the biological pathogens in the biological fluid.
10. The method of claim 9 wherein the composition has at least 250 μM soluble alloxazine.
11. The method of claim 9 wherein the composition has at least 500 μM soluble alloxazine.
12. The method of claim 9 wherein the composition has a concentration of about 580 μM soluble alloxazine.
13. The method of claim 9, wherein said preparing step comprises:
adding an amount of said alloxazine to said aqueous medium, wherein the amount of alloxazine exceeds the saturation point of said alloxazine at 1 atmosphere and 22° C.;heating said aqueous medium to a temperature equal to or greater than 80° C.; andcooling said aqueous medium
14. The method of claim 9, wherein the biological fluid is a blood product.
15. A riboflavin derivative form having a correlation coefficient equal to or less than 0.95 at a wavelength of 525 nm and an absorbance profile as a function of concentration that differs from soluble riboflavin at wavelengths above 500 nm.
16. The riboflavin derivative form of claim 15 produced by the process of combining riboflavin in a aqueous medium having an acidic pH and having a temperature of at least 80° C., then cooling the riboflavin solution.
17. A composition for treating a blood product comprising:
between about 150 μM and about 580 μM soluble alloxazine; anda monovalent salt.
18. The composition of claim 16 wherein the soluble alloxazine is a concentration of about 580 μM.
19. The composition of claim 16 wherein the alloxazine is riboflavin.
20. The composition of claim 16 further comprising sodium bicarbonate.
21. The composition of claim 16 wherein the composition has a pH of from about 4 to about 5.
22. The composition of claim 16 wherein the monovalent salt provides a salinity of at least 0.9%.
Patent Application
20070178437
